Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine

Pregnant and lactating women were excluded from the initial clinical trials in which the safety and efficacy of the BNT162b2 messenger RNA vaccine were evaluated. Consequently, recommendations regarding vaccination of pregnant and lactating women were equivocal.1 Therefore, our aim was to assess whether SARS-CoV-2 immunoglobulins (Igs) can be detected in breastmilk samples of lactating women following SARS-CoV-2 vaccination and whether it can be detected in the serum and oral mucosal secretions of their breastfed infants.